MetaVia extends Phase 1 DA-1726 48mg MAD cohort to 8 weeks; top-line data Q4 2025

MetaVia Inc.

Extended 48 mg MAD cohort to 8 weeks from 4; first patient received fifth weekly dose.
Top-line data from the extended cohort expected in Q4 2025.
Prior 32 mg dose data: mean weight loss 4.3% by Day 26, early satiety in 83% of patients.
Waist circumference reduction of up to 3.9 inches by Day 33 at 32 mg dose.
DA-1726 is a dual GLP1R/GCGR agonist for obesity with a 3:1 balanced activation ratio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.